Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors.
In addition to the Sepsis for which it was developed, the drug Allocetra has other applications such as severe patients with Covid 19 '
autoimmune diseases.
Indication Global Market Size Pre Clinical Phase Marketing
Organ failure associated with Sepsis $33B Phase Ib Completed Phase IIb Initiation Q1 2021
ARDS associated with severe/critical COVID-19 / Non-COVID-19 ARDS $1B (COVID)
$15B (ARDS)
COVID-19 Phase II Ongoing
COVID-19 Phase Ib completed.
goog luck.....
Solid tumors in combination with immune checkpoints $4B Q3 2021